When was Neurogastrx founded?

Neurogastrx was founded in 2012 and raised its 1st funding round 6 years after it was founded.

Where is Neurogastrx located?

Neurogastrx is headquartered in Campbell, United States.

How many employees does Neurogastrx have?

As of Apr 30, 2026, the latest employee count at Neurogastrx is 3.

Is Neurogastrx a funded company?

Neurogastrx is a funded company, having raised a total of $105M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 04, 2018.

When was the latest funding round of Neurogastrx?

Neurogastrx's latest funding was a $***** Series B round on Aug 26, 2021, with participation from 7 investors.

Where does Neurogastrx rank among its competitors?

Neurogastrx ranks 866th amongst 2509 active competitors, of which 862 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Neurogastrx?

Neurogastrx's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Neurogastrx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a dopamine receptor antagonist to treat gastrointestinal disorders. Their lead candidate NG101 is a potent, selective, and peripherally restricted dopamine D2/D3 receptor antagonist for the treatment of gastroparesis. Another product Fexuprazan is a potassium-competitive acid blocker for the treatment of erosive esophagitis.

Website: neurogastrx.com
Email ID: *****@neurogastrx.com

Key Metrics

Founded Year

2012

Location

Campbell, United States

Stage

Series B

Total Funding

$105M in 2 rounds

Latest Funding Round

Series B, Aug 26, 2021, $*****

Investors

Orbimed & 6 more

Ranked

866^th among 2509 active competitors

Employee Count

3 as on Apr 30, 2026

Similar Companies

Ironwood Pharma & 148 more

View Neurogastrx's full profile

Neurogastrx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neurogastrx, Inc. CIN: 45-5411025 , United States, Active	Apr 18, 2012	-	13 (As on Dec 31, 2022)	-

Neurogastrx has raised a total funding of $105M over 2 rounds. Its first funding round was on Jan 04, 2018. Its latest funding round was a Series B round on Aug 26, 2021 for $*****. 7 investors participated in its latest round. Neurogastrx has 7 institutional investors.

Here is the list of recent funding rounds of Neurogastrx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 26, 2021	5923029	Series B	2574754	3949311	5596180	1256116
Jan 04, 2018	3760245	Series A	3351392	2096006	5AM Ventures & 2 more	6074317

Access funding benchmarks and valuations. Sign up today!

View details of Neurogastrx's funding rounds and investors

The founders of Neurogastrx are Pankaj Jay Pasricha and Cyril De Colle.

Here are the details of Neurogastrx's key team members:

Pankaj Jay Pasricha: Co-Founder of Neurogastrx.
Cyril De Colle: Co-Founder & CSO of Neurogastrx.

View details of Neurogastrx's Founder profiles and Board Members

Neurogastrx's employee count trend

Neurogastrx has 3 employees as of Apr 26. Here is Neurogastrx's employee count trend over the years:

Uncover Neurogastrx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurogastrx include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Neurogastrx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
866th	Neurogastrx 2012, Campbell (United States), Series B	Developer of a dopamine receptor antagonist to treat gastrointestinal disorders	$105M	RTW Investments, Orbimed & 5 others	40/100